ранний ответ на терапию как предиктор эффективности лечения рисперидоном

Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether ‘switching’ early non-responders to another antipsychotic is a better strategy than ‘staying’.

This is the first study to prospectively show that early response/non-response to an antipsychotic (risperidone) is a reliable clinical marker of subsequent clinical outcomes and that a ‘switching’ strategy based on this information may lead to greater clinical improvement than staying on a drug for a longer period in some patients.

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia